© 2021 MJH Life Sciences and Consultant Live. All rights reserved.
May 13, 2021
Patients who received 2 mg or 4 mg of baricitinib maintained vIGA-AD scores through 68 weeks of treatment.
April 26, 2021
A new cross-sectional survey assessment shows patients more severe disease report worse survey outcomes on emotional wellbeing and social activity.
While Janise Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.
Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.
Esther Freeman, MD, PhD, discusses the most frequent cutaneous presentations associated with vaccination.
A study out of Boston observes little to no difference in previous biologic prescription and worsened odds of infection nor death during the pandemic.
An assessment of real-world registry data suggest the biologic provides significant benefit outside of clinical trials.
April 25, 2021
A comparison of pooled phase 3 data showed patients treated with the IL-17A inhibitor fared better than those on ustekinumab, without influence from their PsA status.
A network meta-analysis shows favorability with dupilumab and abrocitinib in efficacy and safety outcomes among adults and adolescents.
The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.